DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Copaxone (Glatiramer Acetate) - Current Clinical Trials

 
 



Copaxone Related Clinical Trials

A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis. [Completed]

Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI [Active, not recruiting]

A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®. [Completed]

Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline [Completed]

Efficacy and Safety of GTR in Comparison to Copaxone® [Completed]

Effects of Copaxone in the Retinal Function in Diabetic Patients After Panphotocoagulation [Active, not recruiting]

Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis [Completed]

Investigating the Neuroprotective Effect of Cop-1 (Copaxone) in Acute Primary Angle Closure [Recruiting]

Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone) [Active, not recruiting]

A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone® [Completed]

Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated Syndrome [Completed]

Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients [Completed]

An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome [Recruiting]

Treatment of Multiple Sclerosis With Copaxone and Albuterol [Completed]

Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer Acetate [Terminated]

Copaxone® Study to Follow Patients From the First Original Study for Safety and Effectiveness. [Active, not recruiting]

Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA). [Completed]

A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose [Completed]

Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone® [Not yet recruiting]

A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Using Alcohol Wipes Prior to Daily Injections of Copaxone®. [Completed]

Comparison of Rituximab Induction Therapy Followed by Glatiramer Acetate Therapy to Glatiramer Acetate Monotherapy for MS [Completed]

A Double Blind Placebo Control Study to Assess the Safety,Tolerability and Efficacy of Copaxone in Crohn's Disease [Recruiting]

Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) [Recruiting]

An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) [Terminated]

Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis [Completed]

Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA) [Completed]

Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-related Macular Degeneration [Suspended]

Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months [Completed]

Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis [Terminated]

Efficacy, Safety, and Tolerability of Plovamer Acetate (Pathway 1) [Completed]

Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis [Completed]

A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon) [Completed]

A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months [Completed]

Copaxone in Age Related Macular Degeneration [Recruiting]

Safety of New Formulation of Glatiramer Acetate [Completed]

Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS) [Completed]

FOCUS Fatigue Outcome in Copaxone USers [Completed]

Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx [Completed]

Rebif� Versus Copaxone� in the Treatment of Relapsing Remitting Multiple Sclerosis [Completed]

Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMS [Terminated]

A Study Comparing Shared Solutions� Plus MS Center Support Versus Shared Solutions� Alone [Completed]

Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine [Completed]

Simvastatin as an add-on Treatment to Copaxone for the Treatment of Relapsing Multiple Sclerosis [Withdrawn]

A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS) [Completed]

High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis [Suspended]

A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to Placebo [Active, not recruiting]

The REbif® vs Glatiramer Acetate in Relapsing Multiple Sclerosis Pharmacogenetics Trial [Completed]

Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis [Completed]

Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate [Completed]

Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate [Recruiting]

Safety and Tolerability of Glatiramer Acetate [Completed]

The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glatiramer Acetate Injections [Withdrawn]

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis [Completed]

Glatiramer Acetate for Multiple Sclerosis With Autoimmune Comorbidities [Completed]

Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer Acetate [Recruiting]

A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple Sclerosis [Completed]

BEYOND: Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose in Multiple Sclerosis (MS) Patients [Completed]

Immune Regulation in Multiple Sclerosis: The Effect of Glatiramer Acetate on MicroRNA Expression in Antigen-Presenting Cells [Active, not recruiting]

Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 mg GA Depot in Subjects With RRMS [Recruiting]

Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis [Enrolling by invitation]

Evaluation of Patient Reported Outcomes in RRMS Patients Candidates for MS Therapy Change and Transitioned to Fingolimod 0.5 mg (EPOC) [Completed]

Therapy Optimization in Multiple Sclerosis (MS) [Completed]

Phase III Randomized, Double-Blind, Placebo-Controlled Study of Copolymer 1 for Relapsing-Remitting Multiple Sclerosis [Completed]

A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy [Completed]

A Prospective Study of Spasticity in Individuals With Multiple Sclerosis [Active, not recruiting]

Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy Change [Completed]

Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects [Withdrawn]

A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability [Withdrawn]

Treatment Interruption of Natalizumab [Completed]

A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple Sclerosis [Completed]

Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study [Recruiting]

Alternative Treatment Paradigm for Natalizumab Trial [Withdrawn]

Cognitive Effects of Immunomodulatory Drugs in MS [Completed]

Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis. [Completed]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015